[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335392-105":59,"doc-detail-335392-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-impact-of-germanys-human-papillomavirus-immunization-program-on-hpv-related-anogenital-diseases-a-retrospective-analysis-of-claims-data-from-statutory-health-insurances","The impact of Germany’s human papillomavirus immunization program on HPV-related anogenital diseases - a retrospective analysis of claims data from statutory health insurances","","Human papillomavirus (HPV) is the most common sexually transmitted infection and drives a broad range of HPV-related diseases, including almost all cervical cancers. Germany has implemented a national HPV immunization program (NIP) with health-insurance reimbursement since 2007, yet real-world population impact data remain limited. This retrospective claims-data study evaluates whether the German NIP reduces HPV-related anogenital disease prevalence among 28–33-year-old women before versus after program introduction.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-impact-of-germanys-human-papillomavirus-immunization-program-on-hpv-related-anogenital-diseases-a-retrospective-analysis-of-claims-data-from-statutory-health-insurances/335392/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-impact-of-germanys-human-papillomavirus-immunization-program-on-hpv-related-anogenital-diseases-a-retrospective-analysis-of-claims-data-from-statutory-health-insurances/335392.png","ImageObject",300,407,{"name":92,"@type":93},"River Wang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What study question does this paper address?","Question",{"text":112,"@type":113},"It examines the population-level impact of Germany’s national HPV immunization program on HPV-related anogenital diseases among young women.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the impact measured?",{"text":117,"@type":113},"Through a retrospective analysis of statutory health-insurance claims data, comparing disease prevalence among 28–33-year-old women before and after program introduction in Germany.",{"name":119,"@type":110,"acceptedAnswer":120},"Which disease outcomes showed significant change after vaccination?",{"text":121,"@type":113},"Significant declines were reported for CIN2+ (cervical high-grade precancers), anogenital warts, and vaginal precancer/cancer.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335392,1790507117,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":4},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","Archives of Gynecology and Obstetrics (2024) 310:2639–2646  \n[https://doi.org/10.1007/s00404-024-07692-y](https://doi.org/10.1007/s00404-024-07692-y)  \nThe impact of Germany’s human papillomavirus immunization program on HPV‑related anogenital diseases: a retrospective analysis of claims data from statutory health insurances  \nElizabeth Goodman1 · Miriam Reuschenbach2 · Tammo Viering3 · Agnes Luzak4 · Wolfgang Greiner5 · Monika Hampl6 · Christian Jacob3  \nReceived: 17 April 2024 / Accepted: 6 August 2024 / Published online: 4 September 2024 © Merck & Co., Inc., Rahway, NJ, USA and its affiliates & Monika Hampl 2024  \nAbstract  \nPurpose Human papillomavirus (HPV) is the most common sexually transmitted infection, responsible for multiple HPVrelated diseases, including almost all cervical cancers. The highly effective HPV vaccination has been recommended under the German HPV national immunization program (NIP) since 2007 and is reimbursed by health insurances. Vaccination uptake rates, however, remain suboptimal and data on the real-world impact of HPV vaccination in Germany are lacking. This study aims to demonstrate the population-level impact of Germany’s NIP on HPV-related anogenital diseases among young women.  \nMethods Retrospective claims data analysis using a classic impact study design comparing disease prevalence among 28-to 33-year-old women before and after introduction of the HPV-immunization program in Germany. Claims data representing approximately two thirds of German health insurances were used. HPV-related disease outcomes included cervical cancer and high grade precancers (cervical intraepithelial neoplasia (CIN) 2+), anogenital warts, as well as vulvar, vaginal, and anal precancer/cancer.  \nResults Significant declines were seen for CIN2+, anogenital warts, and vaginal precancer/cancer. Prevalence of CIN2+ declined 51 . 1% from 0 .92%(95% CI = 0.78%, 1.08%) to 0 .45%(95% CI = 0.38%, 0 .53%) . There was a 38 .6% decline in anogenital warts prevalence from 0.44%(95% CI = 0.36%, 0.54%) to 0.27%(95% CI = 0.22%, 0.32%) and 75.0% decline in vaginal precancer/cancer prevalence from 0.04%(95% CI = 0.02%, 0.07%) to 0.01%(95% CI = 0.00%, 0.02%) . Conclusion The German HPV-immunization program has led to significant declines in female anogenital disease among young women in Germany, highlighting the importance of the vaccination. Moreover, the data suggest that increasing vaccination coverage in Germany could further strengthen the public-health impact of its HPV-immunization program.  \nKeywords Cervical intraepithelial neoplasia (CIN) · Claims data analysis · Genital warts · Germany · HPV vaccination · Human papillomavirus (HPV)  \nAbbreviations  \n4vHPV Quadrivalent human papillomavirus  \nvaccine  \nCI Confidence interval  \nCIN  \nEBM  \nCervical intraepithelial neoplasia Official German Remuneration Scheme for Outpatient Care [Einheitlicher Bewertungsmaßstab]  \n* Elizabeth Goodman [elizabeth.goodman@merck.com](elizabeth.goodman@merck.com)  \n1 Center for Observational and Real-World Evidence, Merck & Co., Inc., Rahway, NJ 07065, USA  \n2 Global Medical and Scientific Affairs, MSD Sharp & Dohme GmbH, Levelingstr. 4a, 81673 Munich, Germany  \n3 EU Real World Evidence, Xcenda GmbH, Lange Laube 31, 30159 Hanover, Germany  \n4 Department of Market Access, MSD Sharp & Dohme GmbH, Levelingstr. 4a, 81673 Munich, Germany  \n5 Department of Health Economics and Health Care Management, Bielefeld School of Public Health, Bielefeld University, Universitätsstraße 25, 33615 Bielefeld, Germany  \n6 Department of Gynecology and Obstetrics, University Hospital of Düsseldorf, Moorenstrasse 5, 40225 Düsseldorf, Germany  \nHPV Human papillomavirus  \nICD-10-GM International Classification of Diseases, 10th Revision, German Modification  \nInGef Institut für angewandte Gesundheits  \nforschung Berlin GmbH  \nNIP National immunization programs  \nOR Odds ratio  \nRRP Recurrent respiratory papillomatosis  \nSHI Statutory Health Insurance  \nSTIKO German Standi","cbCaij7uaQOk5qSO","https://ap.wps.com/l/cbCaij7uaQOk5qSO","pdf",950422,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusion\n# Background\n## HPV infection and disease burden\n## HPV vaccination and German recommendations","[{\"question\":\"What study question does this paper address?\",\"answer\":\"It examines the population-level impact of Germany’s national HPV immunization program on HPV-related anogenital diseases among young women.\"},{\"question\":\"How was the impact measured?\",\"answer\":\"Through a retrospective analysis of statutory health-insurance claims data, comparing disease prevalence among 28–33-year-old women before and after program introduction in Germany.\"},{\"question\":\"Which disease outcomes showed significant change after vaccination?\",\"answer\":\"Significant declines were reported for CIN2+ (cervical high-grade precancers), anogenital warts, and vaginal precancer/cancer.\"}]","The impact of Germany’s human papillomavirus immunization program on HPV-related anogenital diseases - a retrospective analysis of claims data from statutory health insurances | PDF",1790010798]